Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Recruiting now · Phase 2

Conditions studied: Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia

In brief

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.

Key facts

Study ID
NCT00412594
Run by
M.D. Anderson Cancer Center
People needed
150
Starts
2004-06-10
Expected to finish
2027-06-30
Last updated by the study team
2026-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.